Transcenta Holding Ltd 06628
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 1.75
- Day Range
- HKD 1.70–1.78
- 52-Week Range
- HKD 1.17–6.20
- Bid/Ask
- HKD 1.78 / HKD 1.79
- Market Cap
- HKD 776.52 Mil
- Volume/Avg
- 154,500 / 53,734
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 12.16
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 1.31%
Company Profile
Transcenta Holding Ltd is a clinical stage biopharmaceutical company with fully integrated capacities in discovery, research, development and manufacturing. It is developing nine therapeutic antibody molecules for oncology and selected non-oncology indications including bone and kidney disorders. Geographically the company operates in China (the “PRC”) and the USA.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 215
- Website
- https://www.transcenta.com
Comparables
Valuation
|
Metric
|
06628
|
02171
|
02181
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 0.77 | 1.66 | 12.21 |
Price/Sales | 12.16 | — | 19.24 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
06628
|
02171
|
02181
|
|---|---|---|---|
Quick Ratio | 1.50 | 9.49 | 0.69 |
Current Ratio | 1.61 | 9.55 | 1.08 |
Interest Coverage | −33.53 | −174.85 | −20.87 |
Quick Ratio
06628
02171
02181
Profitability
|
Metric
|
06628
|
02171
|
02181
|
|---|---|---|---|
Return on Assets (Normalized) | −22.79% | −28.70% | −20.43% |
Return on Equity (Normalized) | −38.31% | −35.29% | −79.65% |
Return on Invested Capital (Normalized) | −26.22% | −35.38% | −38.37% |
Return on Assets
06628
02171
02181
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Trrhdqltlw | Kgyns | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Jbvqlrwm | Ltsxmq | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Fsvktwfl | Qjwyb | $97.8 Bil | |
MRNA
| Moderna Inc | Yyzzbbyls | Lbwf | $41.3 Bil | |
ARGX
| argenx SE ADR | Pzsdwttd | Wpg | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Zdxlqft | Cyd | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Czcnhlzp | Hdfbgn | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Pwyxbtbr | Lrswrnp | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nzzqfkkjc | Czgkh | $12.5 Bil | |
INCY
| Incyte Corp | Hykmqsy | Cjnhrjb | $11.6 Bil |